{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-25-000062","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.092458+00:00","generated_at":"2026-05-17T05:17:32.027555+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LENZ Therapeutics launches VIZZ eye drop for presbyopia in U.S.; samples shipped","bullets":["VIZZ (aceclidine 1.44%) first FDA-approved aceclidine-based eye drop for presbyopia, now commercially available.","Professional sample distribution to optometrists and ophthalmologists initiated nationwide.","Commercial product shipments to consumers via ePharmacy starting October; broad availability by mid-Q4 2025.","93% of Phase 3 CLARITY trial participants achieved 20/40 near vision within 30 minutes, lasting up to 10 hours.","Addresses ~128 million U.S. adults with blurry near vision; CEO calls it a 'Category of One'."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-25-000062","json":"https://secwatch.observer/filing/0001815776-25-000062.json","markdown":"https://secwatch.observer/filing/0001815776-25-000062.md","text":"https://secwatch.observer/filing/0001815776-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000062/0001815776-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000062/lenz-20250930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:17:32.027555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}